Showing results (131-140 of 197) with videos related to
Sort By:
Pageof 20
Journal of the American Academy of Dermatology|January 7, 2017
Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo- and active comparator-controlled VOYAGE 2 trialKristian Reich, April W Armstrong, Peter Foley, et al.Journal of the American Academy of Dermatology|February 9, 2016
Comparative effectiveness of biologic agents for the treatment of psoriasis in a real-world setting: Results from a large, prospective, observational study (Psoriasis Longitudinal Assessment and Registry [PSOLAR])Bruce E Strober, Robert Bissonnette, David Fiorentino, et al.Dermatology and Therapy|November 4, 2023
Next Generation PDE4 Inhibitors that Selectively Target PDE4B/D Subtypes: A Narrative ReviewAndrew Blauvelt, Richard G Langley, Kenneth B Gordon, et al.Clinical Therapeutics|November 18, 2005
Incidence of infection during efalizumab therapy for psoriasis: analysis of the clinical trial experienceRichard G B Langley, Wayne P Carey, Elyse S Rafal, et al.Dermatology and Therapy|August 23, 2024
Direct and Indirect Effect of Guselkumab on Anxiety, Depression, and Quality of Life in Patients with Moderate-to-Severe Plaque Psoriasis: A Mediation AnalysisApril W Armstrong, Peter Foley, Yan Liu, et al.International Journal of Dermatology|May 17, 2006
Safety of efalizumab in adults with chronic moderate to severe plaque psoriasis: a phase IIIb, randomized, controlled trialKim A Papp, Reni Bressinck, Scott Fretzin, et al.Lancet (London, England)|May 20, 2008
Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)Craig L Leonardi, Alexa B Kimball, Kim A Papp, et al.The New England Journal of Medicine|January 15, 2010
Comparison of ustekinumab and etanercept for moderate-to-severe psoriasisChristopher E M Griffiths, Bruce E Strober, Peter van de Kerkhof, et al.The Journal of Dermatology|October 22, 2019
Consistent responses with guselkumab treatment in Asian and non-Asian patients with psoriasis: An analysis from VOYAGE 1 and VOYAGE 2Kristian Reich, Michael Song, Shu Li, et al.Journal of the American Academy of Dermatology|May 14, 2010
Ustekinumab significantly improves symptoms of anxiety, depression, and skin-related quality of life in patients with moderate-to-severe psoriasis: Results from a randomized, double-blind, placebo-controlled phase III trialRichard G Langley, Steven R Feldman, Chenglong Han, et al.Pageof 20